Michael Paukshto, PhD, CTO and co-founder of Fibralign Corporation, was awarded the 2014 Best New Investigator Award at the 11th Biennial NLN International Conference.
Fibralign has developed and established an end-to-end manufacturing system for production of its BioBridge Collagen Matrix in its GMP facility located in Union City, California.
Fibralign Corp. and leading physicians presented an update on clinical findings and case studies during the 30th World Congress of the International Society of Lymphology (ISL), which was held 15-19 October 2025 in Antalya, Turkey. As part of this session, Dr. Corrado Campisi, incoming President of ISL, presented his prospective randomized clinical study (n=34) using BioBridge with advanced microsurgerical procedures.
This was the second time that ISL hosted a BioBridge-focused session during their bi-annual congress meeting, with the previous session held in Genoa, Italy in September, 2023.
Fibralign Corp. and leading physicians presented an update on clinical findings and case studies during the 30th World Congress of the International Society of Lymphology (ISL), which was held 15-19 October 2025 in Antalya, Turkey. As part of this session, Dr. Corrado Campisi, incoming President of ISL, presented his prospective randomized clinical study (n=34) using BioBridge with advanced microsurgerical procedures.
This was the second time that ISL hosted a BioBridge-focused session during their bi-annual congress meeting, with the previous session held in Genoa, Italy in September, 2023.
Terumo Corporation announced that the first clinical trial conducted in Japan for evaluation the BioBridge® Collagen Matrix in the surgical treatment of lymphedema has reached its endpoint. Terumo is managing and funding clinical studies in Japan which are being used...